Aradigm Corp (NASDAQ:ARDM) CEO InterviewAradigm Corp (NASDAQ:ARDM) CEO InterviewThis interview has expired. Special deals for our readers Be a more profitable investor: Get an Equifax 3-in-1 Credit Report Now! Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing. Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition! LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount. Get FICO Score Watch Now! Click here to get access to powerful investing tools only available at Investor’s Business Daily. Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here Aradigm Corp Aradigm Corporation is a specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Product candidates in development include both the Company’s own products and products under development with collaborators. They consist of approved drugs combined with the Company’s inhalation delivery and/or formulation technologies. The Company’s programs under development include ARD-3100 (Liposomal ciprofloxacin), ARD-3150 (Liposomal ciprofloxacin), ARD-1100 (Liposomal ciprofloxacin) and ARD-1600 (Nicotine). Its collaborative programs under development include ARD-1550 (Inhaled treprostinil), ARD-1500 (Inhaled liposomal treprostinil) and ARD-1700 (combination products). Leave a Reply |
|
Standard Podcast: 
WSR Recommends |
||
| Special Deal for Our Readers (That’s You!) | Jim Cramer: The Clown That Makes You Money | Get Rich with Fibonacci. Learn How to Use Fibonacci Analysis to Trade Better. |
